198 related articles for article (PubMed ID: 36580712)
1. Motor symptoms in Parkinson's disease are related to the interplay between cortical curvature and thickness.
Almgren H; Hanganu A; Camacho M; Kibreab M; Camicioli R; Ismail Z; Forkert ND; Monchi O
Neuroimage Clin; 2023; 37():103300. PubMed ID: 36580712
[TBL] [Abstract][Full Text] [Related]
2. Associations of striatal dopamine transporter binding with motor and non-motor symptoms in early Parkinson's disease.
Yang Z; Xie Y; Dou K; Yang L; Xie A
Clin Transl Sci; 2023 Jun; 16(6):1021-1038. PubMed ID: 36915231
[TBL] [Abstract][Full Text] [Related]
3. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
[TBL] [Abstract][Full Text] [Related]
4. Application of texture analysis to DAT SPECT imaging: Relationship to clinical assessments.
Rahmim A; Salimpour Y; Jain S; Blinder SA; Klyuzhin IS; Smith GS; Mari Z; Sossi V
Neuroimage Clin; 2016; 12():e1-e9. PubMed ID: 27995072
[TBL] [Abstract][Full Text] [Related]
5. Sex Differences in Brain Structure in de novo Parkinson's Disease: A Cross-Sectional and Longitudinal Neuroimaging Study.
Li H; Jia X; Chen M; Jia X; Yang Q
J Parkinsons Dis; 2023; 13(5):785-795. PubMed ID: 37248914
[TBL] [Abstract][Full Text] [Related]
6. Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study.
Ye R; Locascio JJ; Goodheart AE; Quan M; Zhang B; Gomperts SN
Parkinsonism Relat Disord; 2021 Apr; 85():11-16. PubMed ID: 33639572
[TBL] [Abstract][Full Text] [Related]
7. Dopaminergic degeneration induces early posterior cortical thinning in Parkinson's disease.
Sampedro F; Marín-Lahoz J; Martínez-Horta S; Pagonabarraga J; Kulisevsky J
Neurobiol Dis; 2019 Apr; 124():29-35. PubMed ID: 30408592
[TBL] [Abstract][Full Text] [Related]
8. Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease.
Sampedro F; Pérez-González R; Martínez-Horta S; Marín-Lahoz J; Pagonabarraga J; Kulisevsky J
Parkinsonism Relat Disord; 2020 May; 74():43-49. PubMed ID: 32334380
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease.
Theisen F; Leda R; Pozorski V; Oh JM; Adluru N; Wong R; Okonkwo O; Dean DC; Bendlin BB; Johnson SC; Alexander AL; Gallagher CL
Neuroimage Clin; 2017; 16():557-563. PubMed ID: 28971007
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal study investigating the influence of COMT gene polymorphism on cortical thickness changes in Parkinson's disease over four years.
Tajerian A
Sci Rep; 2024 Apr; 14(1):9920. PubMed ID: 38689006
[TBL] [Abstract][Full Text] [Related]
11. Cortical thickness in de novo patients with Parkinson disease and mild cognitive impairment with consideration of clinical phenotype and motor laterality.
Danti S; Toschi N; Diciotti S; Tessa C; Poletti M; Del Dotto P; Lucetti C
Eur J Neurol; 2015 Dec; 22(12):1564-72. PubMed ID: 26212370
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal brain atrophy distribution in advanced Parkinson's disease: What makes the difference in "cognitive status" converters?
Gorges M; Kunz MS; Müller HP; Liepelt-Scarfone I; Storch A; Dodel R; Hilker-Roggendorf R; ; Berg D; Kalbe E; Braak H; Del Tredici K; Baudrexel S; Huppertz HJ; Kassubek J
Hum Brain Mapp; 2020 Apr; 41(6):1416-1434. PubMed ID: 31789477
[TBL] [Abstract][Full Text] [Related]
13. Distinct alterations in Parkinson's medication-state and disease-state connectivity.
Ng B; Varoquaux G; Poline JB; Thirion B; Greicius MD; Poston KL
Neuroimage Clin; 2017; 16():575-585. PubMed ID: 28971008
[TBL] [Abstract][Full Text] [Related]
14. Serum Uric Acid in LRRK2 Related Parkinson's Disease: Longitudinal Data from the PPMI Study.
Bougea A; Koros C; Papagiannakis N; Simitsi AM; Prentakis A; Papadimitriou D; Pachi I; Antonelou R; Angelopoulou E; Beratis I; Bozi M; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
J Parkinsons Dis; 2021; 11(2):633-640. PubMed ID: 33682725
[TBL] [Abstract][Full Text] [Related]
15. Dopamine-related dissociation of cortical and subcortical brain activations in cognitively unimpaired Parkinson's disease patients OFF and ON medications.
Kim J; Zhang K; Cai W; YorkWilliams S; Ua Cruadhlaoich MAI; Llanes S; Menon V; Poston KL
Neuropsychologia; 2018 Oct; 119():24-33. PubMed ID: 30040957
[TBL] [Abstract][Full Text] [Related]
16. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort.
Simuni T; Caspell-Garcia C; Coffey CS; Weintraub D; Mollenhauer B; Lasch S; Tanner CM; Jennings D; Kieburtz K; Chahine LM; Marek K
J Neurol Neurosurg Psychiatry; 2018 Jan; 89(1):78-88. PubMed ID: 28986467
[TBL] [Abstract][Full Text] [Related]
17. Structural connectivity differences in motor network between tremor-dominant and nontremor Parkinson's disease.
Barbagallo G; Caligiuri ME; Arabia G; Cherubini A; Lupo A; Nisticò R; Salsone M; Novellino F; Morelli M; Cascini GL; Galea D; Quattrone A
Hum Brain Mapp; 2017 Sep; 38(9):4716-4729. PubMed ID: 28631404
[TBL] [Abstract][Full Text] [Related]
18. An FP-CIT PET comparison of the difference in dopaminergic neuronal loss in subtypes of early Parkinson's disease.
Song IU; Chung YA; Oh JK; Chung SW
Acta Radiol; 2014 Apr; 55(3):366-71. PubMed ID: 23943629
[TBL] [Abstract][Full Text] [Related]
19. Cortical thinning across Parkinson's disease stages and clinical correlates.
Wilson H; Niccolini F; Pellicano C; Politis M
J Neurol Sci; 2019 Mar; 398():31-38. PubMed ID: 30682518
[TBL] [Abstract][Full Text] [Related]
20. Prediction of depression and anxiety via patient-assessed tremor severity, not physician-reported motor symptom severity, in patients with Parkinson's disease or essential tremor who have undergone deep brain stimulation.
Achey RL; Yamamoto E; Sexton D; Hammer C; Lee BS; Butler RS; Thompson NR; Nagel SJ; Machado AG; Lobel DA
J Neurosurg; 2018 Dec; 129(6):1562-1571. PubMed ID: 29473781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
